1009735-24-3

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 6-bromo-2-methoxynicotinate is used as a building block for the synthesis of various drug compounds. Its unique molecular structure allows for the development of diverse pharmacologically active molecules, making it a valuable asset in the creation of new medications.
Used in Organic Synthesis:
Methyl 6-bromo-2-methoxynicotinate is used as a key starting material in organic synthesis. Its unique chemical reactivity and the presence of a bromine atom and a methoxy group make it a versatile intermediate for the preparation of a wide range of organic compounds.
Used in Medicinal Chemistry:
Methyl 6-bromo-2-methoxynicotinate is used in medicinal chemistry for the development of potential therapeutic agents. Its unique properties and reactivity make it an essential component in the design and synthesis of new drugs with potential therapeutic applications.
Overall, Methyl 6-bromo-2-methoxynicotinate plays a crucial role in various industries, particularly in drug discovery and development, due to its unique chemical reactivity and biological properties.

Upstream product

• 40473-07-2 6-bromo-2-methoxypyridine 
• 1060806-62-3 6-bromo-2-methoxynicotinic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 1246765-98-9 (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinamide 

Relevant academic research and scientific papers

Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5- dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist

A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na+/K+ ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na +/K+ ratio and demonstrated this novel compound acts as an MR antagonist.

4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES

Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.